Want a full personalised taper protocol?

This page shows a quick schedule for this drug. For the guided path — pre-taper risk quiz, formulation-aware steps, and email delivery — start from the main calculator.

Lexapro / Cipralex (Escitalopram) Tapering Guide

Lexapro (escitalopram) is an SSRI antidepressant, sold as Lexapro in the US and Cipralex in the UK and EU. It is a common first-line option for depression and generalised anxiety disorder. This guide and medication taper calculator help you plan how to taper off Lexapro safely with your prescriber.

Dosage

Escitalopram tablets come in 5 mg, 10 mg, and 20 mg strengths (10 mg and 20 mg are often scored). Licensed liquids include Lexapro 5 mg/5 mL (1 mg/mL) in the US and Cipralex 20 mg/mL drops in the UK/EU. Below about 5 mg, splitting tablets is unreliable — use the liquid for small final steps.

Escitalopram is potent per milligram and has a high withdrawal-severity rating in population data, so gradual hyperbolic reductions matter especially at the low end of the taper.

Escitalopram taper schedule

Choose a common starting dose to preview the full hyperbolic schedule — free, no email required. This schedule has 22 steps and takes about 42 weeks in total; your prescriber may adjust the pace based on how you feel.

Starting dose

Selected start: 10 mg/day · 1× daily
Taper speed: Moderate
Region (formulations): US; Tablet/liquid products used for dosing tips — not your location. Example uses US formulary; change region in the custom builder.
Modelled occupancy at start: ~78.3%

Swipe sideways to see every column.

Step	Daily (mg)	How to take it	Per dose × 1/day	Hold (weeks)
0	10	Your current dose — hold steady before step 1.	10 mg × 1	—
1	8	Measure 8 mL of 1 mg/mL oral solution (≈ 8 mg active ingredient). Use an oral syringe; confirm concentration on the bottle.	8 mg × 1	2
2	5	Take 1 × 5 mg Lexapro tablet (5 mg active ingredient total).	5 mg × 1	2
3	4.3	Measure 4.3 mL of 1 mg/mL oral solution (≈ 4.3 mg active ingredient). Use an oral syringe; confirm concentration on the bottle.	4.3 mg × 1	2
4	3.75	Measure 3.75 mL of 1 mg/mL oral solution (≈ 3.75 mg active ingredient). Use an oral syringe; confirm concentration on the bottle.	3.75 mg × 1	2
5	3.3	Measure 3.3 mL of 1 mg/mL oral solution (≈ 3.3 mg active ingredient). Use an oral syringe; confirm concentration on the bottle.	3.3 mg × 1	2
6	2.9	Measure 2.9 mL of 1 mg/mL oral solution (≈ 2.9 mg active ingredient). Use an oral syringe; confirm concentration on the bottle.	2.9 mg × 1	2
7	2.55	Measure 2.55 mL of 1 mg/mL oral solution (≈ 2.55 mg active ingredient). Use an oral syringe; confirm concentration on the bottle.	2.55 mg × 1	2
8	2.25	Measure 2.25 mL of 1 mg/mL oral solution (≈ 2.25 mg active ingredient). Use an oral syringe; confirm concentration on the bottle.	2.25 mg × 1	2
9	2	Measure 2 mL of 1 mg/mL oral solution (≈ 2 mg active ingredient). Use an oral syringe; confirm concentration on the bottle.	2 mg × 1	2
10	1.8	Measure 1.8 mL of 1 mg/mL oral solution (≈ 1.8 mg active ingredient). Use an oral syringe; confirm concentration on the bottle.	1.8 mg × 1	2
11	1.6	Measure 1.6 mL of 1 mg/mL oral solution (≈ 1.6 mg active ingredient). Use an oral syringe; confirm concentration on the bottle.	1.6 mg × 1	2
12	1.45	Measure 1.45 mL of 1 mg/mL oral solution (≈ 1.45 mg active ingredient). Use an oral syringe; confirm concentration on the bottle.	1.45 mg × 1	2
13	1.3	Measure 1.3 mL of 1 mg/mL oral solution (≈ 1.3 mg active ingredient). Use an oral syringe; confirm concentration on the bottle.	1.3 mg × 1	2
14	1.15	Measure 1.15 mL of 1 mg/mL oral solution (≈ 1.15 mg active ingredient). Use an oral syringe; confirm concentration on the bottle.	1.15 mg × 1	2
15	1.05	Measure 1.05 mL of 1 mg/mL oral solution (≈ 1.05 mg active ingredient). Use an oral syringe; confirm concentration on the bottle.	1.05 mg × 1	2
16	0.95	Measure 0.95 mL of 1 mg/mL oral solution (≈ 0.95 mg active ingredient). Use an oral syringe; confirm concentration on the bottle.	0.95 mg × 1	2
17	0.85	Measure 0.85 mL of 1 mg/mL oral solution (≈ 0.85 mg active ingredient). Use an oral syringe; confirm concentration on the bottle.	0.85 mg × 1	2
18	0.75	Measure 0.75 mL of 1 mg/mL oral solution (≈ 0.75 mg active ingredient). Use an oral syringe; confirm concentration on the bottle.	0.75 mg × 1	2
19	0.65	Measure 0.65 mL of 1 mg/mL oral solution (≈ 0.65 mg active ingredient). Use an oral syringe; confirm concentration on the bottle.	0.65 mg × 1	2
20	0.55	Measure 0.55 mL of 1 mg/mL oral solution (≈ 0.55 mg active ingredient). Use an oral syringe; confirm concentration on the bottle.	0.55 mg × 1	2
21	0.5	Measure 0.5 mL of 1 mg/mL oral solution (≈ 0.5 mg active ingredient). Use an oral syringe; confirm concentration on the bottle.	0.5 mg × 1	2

Rows highlighted: larger occupancy drop than target — consider smaller steps or longer holds. If symptoms are intolerable, return to the previous dose and talk to your prescriber.

Want a copy to keep?

The full escitalopram schedule is already shown below. Enter your email to also receive a PDF and HTML copy you can save or share with your prescriber — optional, and we never gate the schedule behind it.

It's not a substitute for medical advice. This calculator can help you visualise a tapering schedule but before making any changes to your medication plan it's necessary to consult a medical professional. Ask a psychiatrist — available after you request your protocol.

Dose vs occupancy

This taper is spread across 22 gradual steps. The curve below shows why the last few milligrams matter most: at low doses, small dose changes produce large drops in serotonin-transporter occupancy.

What this shows: the non-linear relationship between dose and serotonin transporter (SERT) occupancy. The curve is flat at high doses — most transporters are already blocked, so a dose cut has little biological impact — and much steeper at low doses, where even a 1–2 mg reduction causes a disproportionately large drop in occupancy. Your taper steps are spaced along this curve so each step removes a similar amount of occupancy.

Modelled Hill-curve occupancy — illustrative only. PET-derived parameters vary by study; your prescriber may use different clinical targets. Small mg changes near zero can still produce large occupancy shifts.

How to Taper Off Lexapro (Escitalopram) Safely

How to taper off Lexapro (escitalopram) safely starts with recognising its potency: small milligram changes can mean large shifts in serotonin-transporter occupancy. Coming off escitalopram is usually easiest with a hyperbolic taper schedule — shrinking steps planned with your prescriber — rather than a linear “cut by 5 mg” plan. The calculator above builds that schedule for your dose; this guide covers what to expect when you wean off Lexapro.

Escitalopram is the S-enantiomer of citalopram and is among the more potent SSRIs milligram-for-milligram. Its half-life is about 27–32 hours. People often look up how to get off antidepressants after a period of stability; for Lexapro, the evidence base points to gradual, occupancy-based reductions (Horowitz & Taylor, 2019; Maudsley Deprescribing Guidelines 2024; NICE NG222).

What coming off Lexapro actually feels like, week by week

Escitalopram clears over a few days, so withdrawal after an oversized cut usually shows up within two to five days: dizziness, brain zaps, irritability, tearfulness, insomnia or vivid dreams, flu-like aches, and a surge of anxiety that can feel like the original problem returning.

Because Lexapro is potent, many people sail through 20 → 10 mg and then struggle from 10 mg downward. In a well-paced taper each step should cause only a brief wobble that settles within one to two weeks. The final few milligrams often take as long as the entire upper half of the plan.

“The 20 to 10 mg drop was nothing. Ten to five nearly floored me — dizzy, weepy, zapping. Doing 5 mg down in one-milligram drops with the liquid was night and day.”

— paraphrased from patient forums

“I kept being told 5 mg is "a baby dose, just stop." For me the side effects of coming off Lexapro were worst right at that last step.”

— paraphrased from patient forums

Withdrawal or relapse — how to tell them apart

Withdrawal from escitalopram typically starts days after a reduction, features physical and sensory symptoms (zaps, dizziness), and eases quickly if you return to the previous dose. Relapse of depression or anxiety tends to emerge weeks later, mirrors your original illness, and does not resolve promptly with reinstatement (Cosci & Chouinard, 2020).

Lexapro taper schedules by starting dose (20, 10, 5 mg)

Lexapro comes as 5, 10, and 20 mg tablets plus a licensed oral solution. A linear “20 → 15 → 10 → 5 → 0” plan front-loads too little and back-loads far too much occupancy change. The hyperbolic schedule above corrects this automatically; use the notes below — high starting dose first — as context.

From 20 mg: the first steps (20 → 15 → 10) are comfortable for most people because occupancy is near-plateau up here. A Lexapro taper schedule from 20 mg spends most of its careful work in the 10-and-under range.

From 10 mg: this is the real work. How to taper off Lexapro 10 mg means planning the descent through roughly 7, 5, 3, 2, 1 mg — steps that need the liquid, not a tablet-splitter alone.

From 5 mg: yes, you usually still need to taper. Five milligrams still occupies a large fraction of transporters, so stopping from 5 mg is effectively a large final step — liquid micro-doses keep the last reductions proportional.

Build your schedule from your dose →

If it gets worse: pausing and reinstatement

If symptoms after a cut are intolerable, hold longer at the current dose, partially reinstate the last stable dose, or contact your prescriber if mood is deteriorating. Escitalopram's ~30-hour half-life means relief after reinstatement often arrives within one to two days.

Once settled, resume from the tolerated dose with smaller steps and longer holds. Pausing is a normal part of learning your personal taper schedule, not a failure. Do not change your dose without clinical advice.

Liquid and small doses of escitalopram

Below 5 mg, tablet splitting is imprecise for a drug this potent. Licensed Lexapro oral solution (or a compounded liquid) lets you measure 3, 2, 1 mg and below with an oral syringe.

Plan the switch to liquid before you need the first sub-tablet step so there is no gap in the taper. The final milligrams of coming off escitalopram are where equal occupancy steps matter most.

The bottom line

The art of coming off Lexapro is respecting its potency: cruise through the top, then slow sharply as you wean off through 10 mg and below. Pair the hyperbolic schedule above with liquid for the last steps, and keep your prescriber in the loop.

Key facts about hyperbolic antidepressant tapering

The calculator algorithm is based on peer-reviewed research and has been reviewed by our medical advisors to ensure the accuracy of the tapering model.

72%
discontinued their antidepressant using hyperbolic tapering strips in a real-world study
71% of the same people had previously tried to stop at least once and been unsuccessful; the study did not record which method those earlier attempts used. Figures come from tapering-strip research and may not generalise to every taper.
Source: Groot et al., Therapeutic Advances in Psychopharmacology 2021
56 days
median taper length in that tapering-strip study — not a target; many people taper over 6–12 months or longer
This median reflects tapering-strip use in one study. Your timeline depends on how long you have taken the medication, your withdrawal symptoms, and previous attempts — slower is often safer.
Source: Groot et al., Therapeutic Advances in Psychopharmacology 2021
10%
serotonin transporter occupancy per tapering step
This linear reduction prevents withdrawal. Slower, more gradual tapering over several months has shown greater success in reducing withdrawal symptoms than short tapers.
Source: Horowitz et al., The Lancet Psychiatry 2019

Claro — tapering companion

A protocol isn’t enough — you need support.

Tapering can take months, sometimes years. Claro helps you track each step, log symptoms, and spot when a reduction was too fast — with psychiatrist-reviewed guidance. Join early access while we launch the app.

Why an AI companion for tapering? →

Frequently asked questions about escitalopram

Common questions about how to taper off escitalopram, hyperbolic schedules, and withdrawal — written for people who want to come off antidepressants safely with their prescriber.

How do you taper off Lexapro (escitalopram)?

Lexapro tablets exist in 5, 10, and 20 mg strengths. Below 5 mg you should use the licensed liquid (Lexapro 5 mg/5 mL in the US; Cipralex 20 mg/mL drops in the UK and EU). Many clinicians recommend taking the last steps in increments of 1-2 mg every 2-4 weeks, because the dose-occupancy curve for escitalopram is especially steep below 5 mg (Suhara et al., 2003).

Do you have to taper off 5 mg Lexapro?

Yes — 5 mg is not a negligible dose. Escitalopram is the most potent SSRI per milligram, so 5 mg still occupies a large share of serotonin transporters. Stopping straight from 5 mg is effectively a big final step and is the point most likely to cause withdrawal. Taper it down through 3, 2, and 1 mg using the liquid rather than dropping it.

How long does it take to taper off Lexapro?

Most people take several months to taper off Lexapro, with each dose held for 2-4 weeks. Because escitalopram is so potent at low doses, the sub-5 mg part of the taper often takes as long as the entire 20-to-5 mg descent. There is no fixed schedule — the pace should follow how you feel, guided by your prescriber.

Can you stop Lexapro cold turkey?

Stopping Lexapro cold turkey is discouraged. Its moderate half-life (~27-32 hours) means abrupt discontinuation commonly causes withdrawal within days — dizziness, brain zaps, nausea, and low mood — and the effect is amplified by the drug's potency at low doses. If you have stopped suddenly and feel unwell, speak to your prescriber about reinstating and tapering gradually.

What is an antidepressant tapering calculator?

An antidepressant tapering calculator is a free online medication taper calculator that turns your current dose into a step-by-step plan for reducing it over time. The Claro calculator uses the hyperbolic method: each step removes a similar percentage of receptor occupancy rather than the same number of milligrams. The result is a personalised schedule you can review with your prescriber when you decide to wean off antidepressants.

Why use a tapering calculator?

A medication taper calculator turns receptor-occupancy research into a concrete hyperbolic taper schedule you can read in minutes. It is especially useful when you want to come off antidepressants gradually, because the last few milligrams cause the largest change in modelled occupancy. Use it to preview steps, plan liquid or split-tablet doses, and bring a printable plan when you wean off antidepressants with your prescriber.

How does an antidepressant taper calculator work?

The calculator models how much of your serotonin (or noradrenaline) transporter is occupied at each dose using a Hill-equation curve fitted to published PET studies. It then chooses dose reductions so that each step removes a roughly equal amount of occupancy — the hyperbolic method described by Horowitz and Taylor (2019). The schedule is then rounded to doses you can actually achieve with available tablets, capsules, or liquids in your region.

What is hyperbolic tapering and why is it recommended?

Hyperbolic tapering means reducing your dose by smaller and smaller milligram amounts as you get lower, so the change in receptor occupancy at each step stays about the same. It is recommended because antidepressants follow a hyperbolic dose-response curve: at low doses, small milligram changes have outsized effects. Hyperbolic tapering is endorsed in the Maudsley Deprescribing Guidelines (2024), the UK NICE NG222 guideline, and the Dutch multidisciplinary deprescribing document.

What is the safest way to taper off antidepressants?

The safest way is gradual, supervised, and individualised. Work with a prescriber, hold each dose for at least 2-4 weeks before reducing again, and use liquid or compounded formulations once tablets cannot be split small enough. If symptoms become severe, return to the previous stable dose, allow time to settle, then resume with smaller steps. This calculator is educational; do not change medication without clinical supervision.

How slowly should antidepressants be reduced?

Most people benefit from reductions of around 5-10% of the previous dose every 2-4 weeks, and even more slowly toward the end of the taper. Higher-risk drugs — paroxetine, venlafaxine, and duloxetine — typically need slower steps and longer holds. There is no fixed timeline: many people take 6-12 months to fully get off antidepressants and some take longer, especially after years of treatment.

What are common antidepressant withdrawal symptoms?

The most commonly reported antidepressant withdrawal symptoms include dizziness, "brain zaps" (brief electric-shock sensations), nausea, fatigue, insomnia, vivid dreams, headaches, irritability, anxiety, and mood swings. A 2024 Lancet Psychiatry meta-analysis (Henssler et al.) estimated discontinuation symptoms in around 31% of people, with about 2.8% experiencing severe symptoms. Earlier work (Davies & Read, 2019) reported higher rates of 56% across surveyed populations.

What is the difference between antidepressant withdrawal and relapse?

Withdrawal usually starts within days of a dose reduction, includes physical symptoms like dizziness or brain zaps, and improves when you reinstate the previous dose. Relapse of the original condition typically appears weeks later, is dominated by your original symptoms, and is not relieved within hours by reinstating. The Cosci & Chouinard (2020) framework is the standard taxonomy clinicians use to tell the two apart.

Is it dangerous to stop antidepressants cold turkey?

Stopping antidepressants cold turkey is widely discouraged. Sudden discontinuation increases the risk of severe withdrawal symptoms, including dizziness, brain zaps, and emotional changes, and can trigger reinstatement. Short half-life drugs such as paroxetine and venlafaxine carry the highest risk. If you have already stopped abruptly and feel unwell, contact your prescriber; reinstating the previous dose and then tapering more gradually is the standard recommendation.

Why are the last antidepressant dose reductions often the hardest?

Because the dose-occupancy curve is hyperbolic. At low doses, a 1-2 mg change can produce as much receptor change as a 10-20 mg change at higher doses. This is why people often feel fine for most of the taper and then struggle at the end. A medication taper calculator addresses this by making the final steps in tenths of a milligram, which usually requires a liquid formulation or compounded preparation.

Which antidepressants are hardest to taper off?

Paroxetine (Paxil/Seroxat) and venlafaxine (Effexor) are most often reported as the hardest antidepressants to come off, followed by duloxetine (Cymbalta). They share short half-lives and steep dose-occupancy curves, so missed doses or sharp reductions can trigger withdrawal symptoms within days. Fluoxetine (Prozac), with its very long half-life, is generally the easiest and is sometimes used as a "bridge" when switching off shorter-acting drugs.

Need a different dose or speed?

Use the guided builder to enter your current dose, region, and taper preset — then email your personalised protocol.

Request custom protocol →

Clinical references

[1]Horowitz MA, Taylor D. Tapering of SSRI treatment to mitigate withdrawal symptoms. The Lancet Psychiatry 2019.doi:10.1016/S2215-0366(19)30032-XProposes hyperbolic dose reduction based on receptor-occupancy curves; the methodological basis of every modern taper calculator.
[2]Horowitz MA, Taylor D. The Maudsley Deprescribing Guidelines. Wiley 2024.doi:10.1002/9781394291052Per-drug operational manual for hyperbolic tapering across SSRIs, SNRIs, benzodiazepines, gabapentinoids, and antipsychotics.
[3]Davies J, Read J. A systematic review into the incidence, severity and duration of antidepressant withdrawal effects. Addictive Behaviors 2019.doi:10.1016/j.addbeh.2018.08.027Systematic review: 56% of people who discontinue antidepressants experience withdrawal effects; 46% rate them as severe.
[4]Henssler J et al. Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis. The Lancet Psychiatry 2024.doi:10.1016/S2215-0366(24)00133-0Meta-analysis of 79 studies (≈21,000 patients): pooled incidence of discontinuation symptoms ~31%; severe symptoms ~2.8%.
[5]Groot PC, van Os J. Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study. Therapeutic Advances in Psychopharmacology 2021.doi:10.1177/2045125321103932772% of patients successfully discontinued antidepressants after switching to the hyperbolic model; 71% had previously failed to come off without tapering strips.
[6]Groot PC, van Os J. Antidepressant tapering strips to help people come off medication: real-world outcomes. Therapeutic Advances in Psychopharmacology 2023.doi:10.1177/20451253231171518Of 1,194 patients using hyperbolic taper strips after previous failed attempts, ~71% successfully discontinued their antidepressant.
[7]Framer A. What I have learnt from helping thousands of people taper off antidepressants and other psychotropic medications. Therapeutic Advances in Psychopharmacology 2021.doi:10.1177/2045125321991274Describes the "windows and waves" pattern of withdrawal recovery and supports patient-led pacing.
[8]Hengartner MP et al. Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives. Therapeutic Advances in Psychopharmacology 2020.doi:10.1177/2045125320967183Descriptive analysis of 69 protracted withdrawal cases: median duration 79 weeks; 47% report suicidality during withdrawal.
[9]Cosci F, Chouinard G. Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications. Psychotherapy and Psychosomatics 2020.doi:10.1159/000506868Taxonomy distinguishing new withdrawal symptoms, rebound, and persistent post-withdrawal disorder; the standard framework for withdrawal vs. relapse.
[10]Kalfas M et al. Incidence and Nature of Antidepressant Discontinuation Symptoms. JAMA Psychiatry 2025.doi:10.1001/jamapsychiatry.2025.1362Recent meta-analysis: dizziness was the most common discontinuation symptom in the first 2 weeks after stopping antidepressants, followed by nausea, vertigo, and nervousness.
[11]Gabriel M, Sharma V. Antidepressant discontinuation syndrome. Canadian Medical Association Journal 2017.doi:10.1503/cmaj.160991Clinical review of antidepressant discontinuation syndrome: onset within days of dose reduction, typical symptom course, and management.
[12]Papp A, Onton J. Brain Zaps: An Underappreciated Symptom of Antidepressant Discontinuation. The Primary Care Companion for CNS Disorders 2018.doi:10.4088/pcc.18m02311Characterises "brain zaps" — brief electric-shock sensations — as a common antidepressant discontinuation symptom.
[13]Wang J, Cosci F. Acute and persistent withdrawal syndromes following discontinuation of antidepressants in children and adolescents: a systematic review. Therapeutic Advances in Psychopharmacology 2025.doi:10.1177/20451253251404780Systematic review of acute and persistent antidepressant withdrawal syndromes; reinforces reducing only when stable and under supervision.
[14]Horowitz M, Taylor D. Distinguishing relapse from antidepressant withdrawal: clinical practice and antidepressant discontinuation studies. BJPsych Advances 2022.doi:10.1192/bja.2021.62Frames how clinicians can distinguish antidepressant withdrawal from relapse of the underlying condition.
[15]Sørensen A, Ruhé HG, Munkholm K. The relationship between dose and serotonin transporter occupancy of antidepressants — a systematic review. Molecular Psychiatry 2021.doi:10.1038/s41380-021-01285-wSystematic review of dose–SERT-occupancy relationships across antidepressants; confirms the hyperbolic curve underlying proportional tapering.
[16]Reeve R, Turner JR. Pharmacodynamic models: parameterizing the Hill equation, Michaelis-Menten, the logistic curve, and relationships among these models. Journal of Biopharmaceutical Statistics 2013.doi:10.1080/10543406.2012.756496Explains how the Hill equation, Michaelis-Menten, and logistic models relate — the mathematical basis for the occupancy curve used here.
[17]Preskorn SH. The use of biomarkers in psychiatric research: how serotonin transporter occupancy explains the dose-response curves of SSRIs. Journal of Psychiatric Practice 2012.LinkShows how SERT occupancy explains the non-linear dose–response curves of SSRIs.
[18]Cohrs D, Shapiro B. The relationship between SERT occupancy and extracellular serotonin concentration is hyperbolic, not linear: implications for safely tapering SRI antidepressants. SSRN (preprint) 2026.doi:10.2139/ssrn.6176553Argues the SERT-occupancy to serotonin relationship is itself hyperbolic, reinforcing proportional (hyperbolic) tapering.
[19]Moncrieff J et al. Evidence on antidepressant withdrawal: an appraisal and reanalysis of a recent systematic review. Psychological Medicine 2025.doi:10.1017/S0033291725100652Reappraisal of recent withdrawal-incidence evidence; relevant to how withdrawal rates are interpreted.
[20]Wilson E, Lader M. A review of the management of antidepressant discontinuation symptoms. Therapeutic Advances in Psychopharmacology 2015.doi:10.1177/2045125315612334Practical review of how to manage antidepressant discontinuation symptoms, including tapering and reinstatement.
[21]Groot PC, van Os J. Outcome of antidepressant drug discontinuation with tapering strips after 1–5 years. Therapeutic Advances in Psychopharmacology 2020.doi:10.1177/2045125320954609Long-term follow-up (1–5 years) of patients who discontinued antidepressants using hyperbolic taper strips.
[22]Gury C, Cousin F. Pharmacokinetics of SSRI antidepressants: half-life and clinical applicability. L'Encéphale 1999.LinkHalf-life data for SSRIs — explains why short-half-life drugs (paroxetine, venlafaxine) provoke faster withdrawal.
[23]Mayo Clinic. Antidepressant withdrawal: Is there such a thing?. Mayo Clinic — Expert Answers 2024.LinkPatient-facing explainer on antidepressant discontinuation symptoms and gradual tapering.
[24]NHS Scotland — Right Decision Service. Antidepressants — quality prescribing: difficulty withdrawing from an SSRI/SNRI. NHS Scotland 2024.LinkNHS Scotland guidance on recognising and managing difficulty withdrawing from SSRIs/SNRIs.
[25]The Carlat Psychiatry Report. Clinical pearls for hyperbolic tapering of psychiatric medications in older adults. The Carlat Report 2024.LinkPractical clinical pearls for applying hyperbolic tapering, including in older adults.
[26]Royal College of Psychiatrists. Stopping antidepressants — information for patients and carers. Royal College of Psychiatrists 2024.LinkRCPsych patient-facing guidance on coming off antidepressants safely.
[27]Meyer JH et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses. American Journal of Psychiatry 2004.doi:10.1176/appi.ajp.161.5.826PET-imaged SERT occupancy data for citalopram, sertraline, paroxetine, fluoxetine, and venlafaxine — the empirical basis for the hyperbolic curves in this calculator.
[28]Suhara T et al. High levels of serotonin transporter occupancy with low-dose clomipramine and escitalopram. Archives of General Psychiatry 2003.doi:10.1001/archpsyc.60.4.386Demonstrates high SERT occupancy at very low SSRI doses — supports the steep, hyperbolic dose-occupancy curve.
[29]National Institute for Health and Care Excellence (NICE). Depression in adults: treatment and management. NICE guideline [NG222]. NICE 2022.LinkUK national guideline endorsing proportional (hyperbolic) tapering and the use of liquid formulations to enable small final doses.
[30]Royal College of Psychiatrists. Stopping antidepressants — position statement (CR225). Royal College of Psychiatrists 2020.LinkRCPsych acknowledges withdrawal can be severe and long-lasting; recommends slow, individualised tapers.
[31]NHG et al. Multidisciplinary document: Discontinuation of SSRIs and SNRIs (2018; revised 2023). Multidisciplinary Document (Netherlands) 2018.LinkFirst national guideline to explicitly endorse hyperbolic tapering and the use of taper strips (compounded by Regenboog Apotheek).
[32]Medicines and Healthcare products Regulatory Agency (MHRA). Summary of Product Characteristics — SSRI and SNRI products (UK). electronic Medicines Compendium (emc) 2023.LinkAuthoritative UK formulary data (tablet strengths, oral solutions) used to validate the UK region in the calculator.
[33]U.S. Food and Drug Administration. Prescribing information (Structured Product Labeling) for SSRI/SNRI products. FDA / DailyMed 2024.LinkAuthoritative US formulary data (tablet strengths, oral solutions/concentrates) used to validate the US region in the calculator.
[34]Health Canada. Health Canada — Drug Product Database. Health Canada 2024.LinkAuthoritative Canadian formulary data used to validate the Canada region in the calculator.
[35]Therapeutic Goods Administration (TGA). Therapeutic Goods Administration — Australian Register of Therapeutic Goods (ARTG). TGA / ARTG 2024.LinkAuthoritative Australian formulary data used to validate the Australia region in the calculator.
[36]College ter Beoordeling van Geneesmiddelen (CBG-MEB). CBG-MEB — Medicines Information Bank (Netherlands). CBG-MEB 2024.LinkAuthoritative Dutch formulary data; cross-checked with Regenboog Apotheek taper-strip availability.
[37]Regenboog Apotheek, Cinetto. Taperingstrip.com — Regenboog Apotheek. Patient resource (NL) 2024.LinkPioneer of standardised taper strips referenced in the Dutch national guideline.

If you are in crisis or having thoughts of suicide, do not wait for an email response. Find a crisis helpline near you immediately →